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ABSTRACT 
Drug abuse is a main concern for the Royal Government of Cambodia.                
In response to the emerging issues of drug use and related HIV risk, harm 
reduction services have been authorized by the Government. As part of its 
commitment to Universal Access to HIV/AIDS prevention, treatment and care, 
the Government collaborated with NGO’s to pilot a Methadone Maintenance 
Therapy programme (MMT). It was established in July 2010 in a public health 
facility. 
Many studies have shown that treatment retention is one of the key elements to 
the success of a MMT programme. That means if we can keep the patients in 
treatment longer, the patients can get more benefits from the programme such as a 
reduction in, or cessation of, heroin use and improvement in their health status, 
financial issues and their quality of life. Therefore, retention in MMT Treatment is 
very important to prevent the patients from harm related to opiate use. 
The purpose of this study is to explore the level of compliance (Retention) among 
the clients enrolled in Methadone Maintenance Therapy (MMT) at the Center for 
Mental Health and Drug Dependence (CMHDD) in Cambodia and to determine 
the associated factors.  
Concerning the future scale-up of MMT services, the Ministry of Health has also 
advised that a study on the success of MMT at CMHDD should be conducted 
before the MMT programme can be rolled out throughout the country.  
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Having found the associated factors toward retention in MMT, the MMT 
programme can be improved for future replication. 
Method 
This study used a prospective cohort study design. The subject of study were 
injecting and non-injecting opiate users treated at the Center for Mental Health 
and Drug Dependence since 1 July 2010 and the last clients enrolled on 30 June 
2011. All the enrolled clients were followed up through to the end of this study on 
30 September 2011 (15 month cohort study). 
This study is to explore factors associated with methadone maintenance 
compliance (retention) in a group of patients on methadone maintenance therapy 
at the Center for Mental Health and Drug Dependence in Cambodia. 
SPSS version 16 (PASW statistics 16) was used for analysis. The independent 
variables in this study were used and the clinical records of all methadone patients 
in which demographic data is taken to describe the association between Retention 
in MMT treatment and other associated factors. Independent variables are Gender, 
Age, Marital Status, Level of Education, Job Status, Patterns and Types of Drug 
Use, Past History of Drug Use, Duration of Methadone Treatment and Methadone 
Dose. The dependent variable is Compliance Pattern (Retention) to methadone 
treatment and the variables were explored in the analyses.  
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Results 
During this period of study (from 1 July 2010 to 30 June 2011), there were 107 
patients enrolled in treatment and followed up until 30 September 2011. Of 107, 4 
patients died due to other diseases and were not included in this study. Overall 
retention within this study was 82.5% (N = 85) among 103 patients. 3 months,       
6 months, 9 months, 12 months and 15 months retention rates were 92.2%, 80.3%, 
72.4%, 70.7% and 70.7% respectively. Most of non-retention patients quitted the 
treatment at an early stage of this cohort. During the 15 months, there were 18 
patients who were not retained in treatment. Of them, 44.4% (N = 8), 33.3%         
(N = 6), 16.7% (N = 3), 5.6% (N = 1) quit MMT respectively in 3 months, 6 
months, 9 months and 12 months. 
In this study, female, higher educated, married, single opiates use, injecting 
opiates use, using opiates equal to or more than 4 times a day, and living farther 
than 4 km’s from the clinic, had higher retention rates. But there was no 
significant association with retention in Treatment.  
There was a significant association between homeless and higher retention          
(p = 0.0001). It may be due to the fact that they were vulnerable groups and got 
more support from NGOs to facilitate their access to MMT. Methadone dose is 
another predictor variable where it was found that a methadone dose equal to, or 
higher than, 60 mg’s/day/person had a significant association with retention in 
MMT (p = 0.03).  
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Conclusions 
Based on WHO recommendations, one year retention over 60% is considered as 
an effective programme in the reduction of daily opiate use, and an average 
methadone dose of over 60 mg’s/day/person is an effective dose to retain the 
patients in MMT. In this regard, this study found that the 15 month retention rate 
was 70.7% and the average daily dose of methadone was 70 mg’s. Therefore, the 
MMT programme in Cambodia is considered as an effective programme in terms 
of reduction of harm related to opiate use and daily opiate use, and these findings 
should be used as a baseline for rolling out MMT services to other areas. 
To keep the patient better retained in treatment in the early stage, NGO partners 
and the MMT service should provide more orientation to MMT clients before 
starting the methadone dose to make MMT patients understand better about MMT 
treatment and to make better decisions. 
The findings also show that the role of NGOs is also very important to improve 
treatment retention among MMT patients. It should also be recommended to build 
up capacity among MMT service providers in treatment, dosing, and counseling 
to ensure the quality of the MMT service. For future development of MMT, 
collaboration with NGOs working in the community is needed and the 
development of treatment guidelines to ensure compliance of the patients and 
methadone dosing. Other recommendations are that non-medication interventions 
are also predictive factors associated with retention in MMT. 
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Figure 1: Map of Cambodia and Location of the MMT Service  
 
 
Source: Ephotopix (Internet Source)
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CHAPTER I 
1- INTRODUCTION 
1.1 About the health system in Cambodia 
The Kingdom of Cambodia is a South East Asian country that is located in the 
southern portion of the Indochina peninsula. It is bordered by Vietnam to the East, 
Thailand to the Northwest, the Lao PDR to the Northeast and the Gulf of Thailand 
to the Southwest. With a total landmass of 181,035-km’s2, Cambodia currently 
has a population of about 14,805,000 with an estimated rate of population growth 
of 1.7 percent. The life expectancy of Cambodian people is 65 years for women 
and 57 years for men. 95 percent of Cambodian people follow and practice 
Buddhism. The capital city of Cambodia is Phnom Penh, which is the nation’s 
political, cultural, social and economic center. 20 percent of Cambodian people 
are living in urban areas (Ministry of Health, 2008). 
During the Pol Pot Regime, from 1974 to 1979, the country’s health system and 
structure were decimated by the Khmer Rouge. After gaining liberation, 
Cambodia had only 50 medical doctors who had survived and escaped from that 
dark regime. Meanwhile, medical schools and nursing schools appeared, and they 
provided medical training to people. Also, health services were re-established to 
provide treatment and healthcare to the people from the whole country down to 
the community level (Ministry of Health, 1999). 
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Cambodia has 24 provinces and municipalities. According to the national health 
coverage plan, health service delivery is provided by eighty-eight referral 
hospitals and nine hundred health centers, which are based at the commune level. 
These referral hospitals and health centers function and serve as commune health 
centers (Ministry of Health, 2008). The health service provision has been 
vertically integrated from the national to peripheral level. 
 
 
1.2  Situation of Drug Use and HIV in Cambodia 
 
 
 
 
 
 
Source: Ministry of Health, Cambodia, 2008 
As a post conflict country, Cambodia, which has been at full peace from the early 
1990s, faces challenges with many health problems. Those problems are 
Figure 1. 1: Health System Organization 
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HIV/AIDS, malaria, maternal-child health, tuberculosis, high maternal mortality 
rates, high child mortality rates, non-communicable diseases, and other health-
related-problems.  In recent times, illicit drug use has become the nation’s major 
concern for communities and for the Royal Government of Cambodia. In the 
public sector, substance abuse has been put in the non-communicable disease 
programme strategy by the Ministry of Health. The non-communicable disease 
programme strategy has been integrated into the health strategic plan 2008—2015  
(Ministry of Health, 2008). 
Traditionally, drug abuse had not been of any concern in Cambodia. Some 
Cambodian families used drugs as a tradition (Addiction in Sub Mekong Region, 
1998) such as chewing tobacco, and betel especially by women. Usually, betel is 
served to visitors and guests, especially in rural area. In the past some people used 
Cannabis in making soup or by smoking. Heroin use is also reported especially 
among business families. And some traditional healers used Heroin to treat 
diarrhea.  
So far there is no reliable national estimates of the number of drug users in 
Cambodia. Based on experts consensus led by UNAIDS in 2007, illicit drug users 
were accountable for 46,300. Of them about 23,150 (50%) are ATS users, and 
2,900 (6.3%) others are heroin users and 80% of heroin users are Injecting Drug 
Users (National Authority for Combating Drugs, 2008). 
Illicit drug user is the term used to describe a person who is reported by a data 
provider as having used an illicit drug as defined by Cambodian law. The term 
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includes persons sniffing glue or solvents. The term “Drug Use” is used instead of 
“ Drug Abuse” or “ Drug Dependence” because these terms suggest a higher 
standard of assessment, which is generally unavailable in Cambodia. The term 
‘illicit’ is included to emphasize the legal aspect of the description rather than a 
clinical or behavioral confirmation of drug use (National Authority for Combating 
Drugs, 2008). 
Transmission of HIV has a strong connection with injecting drug use. According 
to many studies, in several parts of the world, general healthcare and welfare 
services including the development of community-based health and social 
services, and drug dependence treatment programmes are needed due to the extent 
of HIV/AIDS epidemics amongst injecting drug users (WHO/UNAIDS/UNODC, 
2004). 
Using injecting equipment and drug solutions with other people, having sexual 
contact with IDUs, and sexual activity with people at high risk of HIV make those 
users vulnerable to infection with HIV and other blood-borne viruses. Female 
drug users are prone to HIV as they tend to utilize injecting equipment of their 
partners and find it hard to discuss sexual practice with low risk and condom 
usage as compared to their male counterparts even though they are the majority of 
injecting drug users. Thus, presumably, IDUs engage in the sex industry. 
Transmission of hepatitis C, leading to at least 50-85% of cases of chronic 
infection dominantly occurs through injection drug use. Chronic infection 
advances to liver cirrhosis among almost 7-15% of persons who are infected, 
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while at the same time some advance to liver cancer. More than 70% of HIV 
infections in some countries of Asia and Europe is caused by injection drug use 
compared with only 5 to 10% worldwide. Generally, the use of opioids is found in 
both regions of Asia and Europe (WHO/UNODC/UNAIDS Possition Paper, 
2004). 
Transformation of the pattern from non-injecting to injecting drug use has been 
recorded. WHO, in collaboration with many Government and NGO agencies, 
carried out an International Rapid Assessment Response and Evaluation             
(I-RARE) in 2005 in two urban areas of Phnom Penh and North West Cambodia, 
including Poipet, to inspect drug use and sexual risk patterns that, allow an 
increased risk of contracting HIV by the DU and IDU. Accessibility of sterile 
needles and syringes cost and availability, and a low level of understanding of 
injecting drug use leading to HIV, were ascribed to reuse of needles or syringes 
by the surveyed IDU (WHO/UNODC/UNAIDS Position Paper, 2004). 
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Figure 1. 2: Methamphetamine, Heroin and Cannabis Seizures in Cambodia, 2007 
 
Source: National Authority for Combating Drugs, 2008 
1.3 Different Interventions in Responding to Opiate Dependence 
Methadone belongs to the opioid family of drugs, which includes morphine, 
codeine and heroin. Opioids are classified under depressant drugs as they work by 
slowing down the functions of the central nervous system. Methadone was 
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developed in Germany in 1941 for pain relief. It was then used as a treatment for 
heroin dependence in New York, USA, in 1964 and it is now recognized 
internationally as an effective method for treating opioid dependence (WHO, 
2008). 
Methadone is a synthetic opioid that is typically administered orally as a liquid 
and is a medication most commonly used for substitution therapy of opioid 
dependence. Methadone maintenance treatment is also an extensively researched 
treatment modality. There is strong evidence from research and monitoring of 
service delivery, that substitution maintenance therapy with methadone (MMT) is 
an effective intervention in reducing illicit drug use, reducing mortality, reducing 
the risk of spread of HIV, improving physical and mental health, improving social 
functioning and reducing criminality. Higher doses of methadone are generally 
associated with greater reductions in heroin use than either moderate or low doses 
(WHO/UNODC/UNAIDS Position Paper, 2004). 
Literally, Methadone has been used to detoxify opioid users but it has not been 
effective due to high relapse rates. Traditional abstinence-based approaches to 
drug dependence aim to stop drug use permanently. Few clients achieve 
abstinence, at least in the short term, as many abstinence-based services have 
acknowledged more recently. It is just as important to provide harm reduction 
services to clients who may relapse soon after leaving treatment (WHO, 2006). 
Relapse following detoxification alone is extremely common, and, therefore, 
detoxification rarely constitutes an adequate treatment for substance dependence 
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on its own. Simple detoxification or stopping opioid use is often insufficient; 
therefore, a therapeutic process is required. Detoxification, however, is a first step 
for many forms of longer-term abstinence-based treatments (WHO/UNODC/ 
UNAIDS Position Paper, 2004). 
There are many interventions to reduce harm related to injection drug use. In this 
regard the Government of Cambodia has adopted a Harm Reduction Strategy in 
which there are two main programmes, that of a Needle/-Syringe Programme and 
Opioid Substitution Therapy (OST). Globally, there are two types of medication 
used in Opioid Substitution Therapy, one is Methadone and the other one is 
Buprenorphine. But as Buprenorphine is more expensive than Methadone, 
Cambodia has chosen Methadone even though Buprenorphine is as effective as 
Methadone. Figure 1.3 shows comprehensive services for Drug Users. 
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Figure 1. 3: Drug-Specific Support Services 
 
Source: Lyons, 2010 
Methadone Maintenance Therapy (MMT) is an effective treatment for opiate 
dependence and was initiated in 1964 in the United Sates by Dr. Vincent Dole, 
Dr. Marie Nyswander, and Dr. Mary Jeanne Kreek, at the Rockefeller Institute for 
Medical Research, which is known now as Rockefeller University and 
Rockefeller Hospital. After several studies, it was found to be a safe and effective 
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intervention for opiate addiction. Then, MMT was recommended and integrated 
into multi-modality treatment systems in New York, Illinois, Connecticut, 
Massachusetts, Pennsylvania, and Washington D.C. Since the 1970’s, MMT has 
been more widely disseminated within a national network of addiction treatment 
programmes in the United States (William, 2010). 
1.4 Rationale 
Recently Cambodia has made a great achievement in combating HIV 
transmission. As a result, the prevalence of HIV tested sero—positives has 
decreased from 1.2 % in 2003 to 0.9 % in 2006 among people aged from 15 to 49 
years, although the prevalence of HIV among IDUs is 24.4% (National AIDS 
Authority, 2010). This figure has shown an emerging concern that the spread of 
HIV transmission would occur if there is no proper harm reduction intervention.   
In Cambodia, MMT is the most recent programme and was approved by the 
Ministry of Health (MOH) on 31st March 2010 (Ministry of Health, 2010) through 
an Agreement signed with the Secretariat—General of the National Authority for 
Combating Drug (SG-NACD), the Australian Agency for International 
Development (AusAID), the World Health Organization (WHO) and Family 
Health International (FHI). Referring to the clinical guidelines of MMT in 
Cambodia, the main purposes of MMT in Cambodia are: 
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MMT OBJECTIVES IN CAMBODIA 
• Reduce the patient’s drug use 
• Improve the patient’s health and well-being 
• Reduce transmission of blood-borne infectious diseases (e.g. HIV and 
hepatitis) 
• Reduce death 
• Reduce crime committed by patients 
• Facilitate an improvement in the patient’s social functioning 
• Improve the economic status of patients and their family 
MMT Clinic in Cambodia is a MoH-run demonstration using evidence-based 
international good practices. As planned MMT clinic aimed to provide up to 100 
opiate-dependent people with methadone on a daily basis for up to 12 months. 
The clinic linked MMT clients with other key health programmes, e.g. 
HIV/AIDS, TB, and socio-economic rehabilitation services. A final evaluation 
was also recommended after 12 months of MMT demonstration. If it had success 
outcomes, the Government’s approval would be sought to establish MMT as a 
standard programme in the health system and possibly scale-up to other places in 
the country. 
In order to achieve the above purposes, commitments should be made by clients 
and MMT staff to retain the clients in the treatment as long as possible. In MMT 
programme, Treatment Retention is a key leading to success of the programme in 
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term of harm reduction related to opiates use. It is also vital for this pilot project 
of MMT in Cambodia for the future scale up of MMT services in Cambodia. 
The purpose of this study is to explore the level of compliance (Retention) among 
the clients enrolled in Methadone Maintenance Therapy (MMT) at the Center for 
Mental Health and Drug Dependence (CMHDD) in Cambodia and to determine 
its associated factors. 
MMT programme in Cambodia is collaborated by the Ministry of Health (MoH) 
and non-government organizations (NGOs). The Ministry of Health manages the 
MMT service while NGOs are in charge of referring MMT clients to MMT 
service and follow up with MMT clients in each community. Having found the 
associated factors toward retention in MMT, it would be good evidence for MMT 
programme to improve MMT service for future replication. Figure 1.4 shows 
linkage between MMT and other services. 
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Figure 1. 4: Service Linkage between MMT and other Services 
 
It is recommended to encourage the patients to remain in treatment for at least 12 
months to achieve enduring lifestyle changes (Henry, 2003). A Cochrane Review 
also revealed that methadone is an effective maintenance therapy intervention for 
the treatment of heroin dependence because it retains patients in treatment and 
decreases heroin use better than treatments that do not utilize opioid replacement 
therapy (WHO, 2005). A review of methadone maintenance therapy in Australia 
(1995) found that the patients who had premature termination of MMT tend to 
return to drug use (Commonwealth Department of Human Services and Health, 
1995). 
More recent studies have shown that although MMT does not always result in 
abstinence from drug use, it can improve attendee life including drug use, 
productivity, criminality and HIV risk behaviors. In this regard, it was found that 
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it resulted in the improvement of productivity and less illegal income among 
MMT participants, which may indicate, reduced criminality. So methadone 
maintenance therapy has positive outcomes for opiate injection drug users (Corsi, 
2009). 
Haynes et al., defined that Compliance is the most accepted and one important 
element to show the success of any control and therapeutic programme. However, 
other studies also showed that Compliance to MMT could be associated with 
multiple factors (Ezat, 2009). 
1.5 Aims of the study 
The main hypothesis of this study is to investigate factors associated with 
retention in Methadone Maintenance Therapy. The outcome variable of this study 
is Treatment Retention. That means the patients remained in MMT Treatment 
programme during this study. The predictor variables include gender, age, marital 
status, level of education, living situation, job, history of opiates use, patterns and 
types of drug use, distance to clinic, duration of retention in MMT programme, 
and methadone dose. 
The research questions of this study are: 
• What is the retention rate among the patients attending in MMT 
programme in Cambodia? 
• What are predicting factors significantly associated with retention in MMT 
programme in Cambodia? 
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The aim of this study is to explore factors associated with treatment retention 
among methadone patients in general and to find which predicator variable were 
associated with retention in MMT programme in Cambodia during the period of 
this study. 
The findings of this study would be helpful for evaluation of the MMT 
programme and to gain lessons to improve MMT service in Cambodia. 
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CHAPTER II 
2- LITERATURE REVIEW 
2.1 Opioid Use 
Opioid or Opiate are referred to as either a natural or synthetic drug. Its properties 
or main ingredient are similar to Opium or Morphine. Opium is one type of 
poppy, Papaver Somniferum. It was used as long ago as 4000 B.C. by the 
Sumerians and Assyrians. The use of Opium spread from the Middle East when 
the Islamic religion was expanded. Europeans became aware of opium in the early 
1500’s (Clark, 2008). 
Like other dug use, Opiates are used through many ways such as smoking or 
snorting or injection. The most dangerous route of administration is Opiate 
injection because it can be a cause of transmission of blood borne diseases such as 
HIV and Hepatitis. 
A UNAIDS report (2008) showed that over previous decades in many countries, 
injecting drug users were at high risk of exposure to HIV. Users of drugs were at 
increased risk of premature mortality and blood borne infections. There had been 
several causes of death due to illicit drug use; the most common causes of death 
among such individuals were infection, overdose, suicide, violence and accident 
(Langendam, 2001). The nature of addiction varies from one individual to 
another. Usually individuals who are addicted to drug experience withdrawal 
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symptoms; the severity of the symptoms varies from one individual to another – 
even people who have been using the same amount. Some people experience it 
more easily than others (Getting Through Heroin Withdrawal, 2004).  
The spread of HIV is still a concern regionally as well as globally especially 
among injecting drug users. For instance, the South East Asia and Western Pacific 
regions have been facing major challenges associated with HIV prevalence and its 
preventive measures. WHO released a report on the Practices and Context of 
Pharmacotherapy of Opioid Dependence in the South-East Asian and Western 
Pacific Regions (WHO, 2002). According to reports from China, the prevalence 
of HIV sero-positive is high among of injecting drugs users. Sixty-two percent of 
them were reported to be infected by HIV by the end of 2000, which is equal to 
20,711 cases of injecting drug users infected by HIV. Similar experiences also 
exist in Yunnan Province of China, where 8,317 cases of HIV were reported in 
September 2000, and 70% of those who got a positive result were confirmed to be 
injecting drug users. The result from a three-year study on this issue in a locality 
in Yunnan Province indicated that HIV positivity was sharply rising from 10 to 70 
percent over the study period (WHO, 2002). 
In Indonesia, WHO (2002) reported an increase in HIV prevalence among 
injectors. The results showed that 73% of all new HIV positive tests and 37% of 
new AIDS cases were both among injecting drug users. In Bogor, in West Java 
province, the report showed that one-in-four injectors got a positive HIV 
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test/result, and a study among prisoners in Bali found that 53% of injectors were 
HIV positive. 
Drug injection has also recently been indicated as the main cause of HIV spread in 
such countries as Malaysia, Myanmar, Vietnam and Thailand. In Malaysia, even 
though there is no report of the exact number of injecting drug uses, 85% of HIV 
transmission, equivalent to 65,893 HIV detected cases, is estimated to be caused 
through the injecting of drugs. The situation is even more serious in Myanmar and 
Thailand as more than 50% of the drug injectors in these two countries are 
estimated to be infected with HIV. Similarly, it was reported that approximately 
60% of the injectors in Vietnam are HIV infected and that they accounted for the 
majority of the positive results of HIV tests. 
2.2 Methadone Maintenance Therapy 
Methadone Maintenance Therapy is a part of Harm Reduction Programme. To 
reduce harm related to drug use, there are two main programmes; one is Opioid 
Substitution Therapy (OST), which uses Methadone or Buprenorphine, and the 
other is the Needle/Syringe Programme (NSP), which provides sterile needles and 
syringes for injection drug users.   
Methadone Maintenance Therapy has been considered as an effective approach to 
prevent harm related to opioid use. In 2004, the World Health Organization, 
United Nations Office on Drugs and Crime, and the Joint United Nations 
Programme on HIV/AIDS disseminated a position paper 
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(WHO/UNODC/UNAIDS Position Paper, 2004) on “Substitution Maintenance 
Therapy in the management of opioid dependence and HIV/AIDS prevention”. 
There is strong evidence to prove that methadone maintenance therapy is an 
effective method to reduce illicit drug use, reducing mortality, reducing the spread 
of HIV, improving physical and mental health, improving social functioning and 
reducing criminality (WHO/UNODC/ UNAIDS Position Paper, 2004). 
However, MMT is a maintenance therapy and needs long-term treatment for 
opioid users. MMT patients need to remain in the treatment because retention can 
prevent the patient from harm related to opioid use and is key for a successful 
MMT programme. Thus, retention has been accepted as a measure of the success 
of a MMT programme (Liu, 2009), and to retain the patients in treatment is a 
challenge.  
Evidence shows that treatment compliance in MMT has many different associated 
factors based on different studies (Liu, 2009). 
Based on WHO recommendations, an adequate methadone dose is an important 
factor to retain MMT patients in treatment. In addition, it has been revealed that 
effective methadone maintenance therapy needs to provide adequate doses of 
medication and access to counseling as well as medical and psychiatric care as 
needed (WHO, 2005). 
It was also found that within one year, when 60% to 80% of patients are retained 
in MMT treatment, there will be a reduction of daily illicit opioid use from one 
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hundred percent at the time of starting treatment to less than twenty percent one 
year after MMT treatment is adopted. WHO’s report has shown that Methadone 
maintenance cannot completely eliminate heroin use among clients, but it does 
substantially reduce opioid use. In maintenance treatment, methadone “doses of  
60 mg/day or more have been identified as being most effective in terms of 
retention in treatment and reductions in illicit drug use and criminal behavior” 
(WHO, 2005). 
Similarly, the Department of Mental Health and Substance Abuse (2004) has 
shown that methadone doses in excess of 60 mg/day are most clearly associated 
with better retention in treatment and maximal suppression of heroin use. 
Methadone doses for effective MMT are typically 60-100 mg/day (NIDA, 2006). 
Based on the 10 years of experience of a MMT clinic, a study in Israel found that 
high doses of methadone were associated with retention on MMT. It showed that 
a daily methadone dose of 100 mg or higher is a predicting factor associated with 
retention on MMT (Peles, 2005). 
Riest Dan et al., 2010, also revealed that Methadone dose was a key factor to 
retain MMT patients on treatment. It was stated that episodes with daily doses 
over 100 mg had the highest probability of being retained on treatment at every 
time point. Episodes with a daily dose below 60 mg discontinued earliest (Reist, 
2010). However, WHO/UNODC/UNAIDS (2004) has recommended that the 
maximum daily dose of methadone should be left to the practitioner to judge and 
decide based on the assessment of the individual patient. 
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Some studies (Ezat et al., 2009) found that age is associated with compliance and 
that socio-demographic factors influence compliance. That means the older the 
age, the better the retention. The model revealed that increments of one year of 
age lead to a 6% increment in compliance. Other socio-demographic factors such 
as full time job status and distance to a methadone clinic were also found 
significantly associated with good compliance with therapy, and a history of 
shorter duration of addiction was found to be related to good compliant clients 
(Ezat, 2009). 
Similarly, Carol et al., 2008, found that the odds of remaining in treatment for 730 
days or more increased with age. At retention rates of 20% and lower at 17 weeks, 
and of 85% and higher at 40 weeks, 50% of patients remained in treatment for 730 
days or more. 
Miguel et al., 1997, found that Patient characteristics such as age, race, gender, 
employment, criminal history, severity of addiction, and psychological status, 
have been studied as predictors of retention. 
Among the most important factors are socio-demographic factors; factors related 
to previous history of addiction, factors related to the therapy process, and factors 
related to impact of therapy (Ezat, 2009). 
The illicit use of drugs tremendously impacts on society and brings about many 
serious social issues such as marital and relationship breakup, joblessness, 
homelessness, and child neglect, which often leads to children being brought into 
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the care system. Illicit drug use is also obviously associated with crime. Some 
opioid dependent people commit crimes so that they can afford to use drugs. 
Drug-related crime is estimated to account for half of all crime recorded in the UK 
and incurred annual costs of about £1 billion to the criminal justice system in 
1996 (National Institute for Health and Clinical Excellence, 2007).
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CHAPTER III 
3- METHODOLOGY 
3.1 Design 
This study used a prospective cohort study design to follow a group of Opiate 
Users enrolled in MMT. Injecting and non-injecting opiate users who were 
enrolled and treated at the Center for Mental Health and Drug Dependence since  
1 July 2010 until 30 June 2011were recruited in this study. All MMT clients were 
recruited and followed up through the end of this study in 30 September 2011.  It 
is an analysis of risk factors and follows a group of people who received treatment 
at CMHDD, and uses correlations to identify associated factors of retention.  
• Retention is an outcome variable of this study. It is a pattern of patient 
receiving regular methadone dose, having or missed methadone dose equal 
or less than 5 consecutive days any time in the period of study; considered 
as Retention. In this regard the patients still are retained in treatment. 
• The pattern of patient receiving methadone is not regular and having 
missed dose or missed methadone dose more than 5 consecutive days at 
anytime of treatment during the study time is considered as Non 
Retention or Dropout. In this regard, the patient has terminated treatment 
and a new dose must be started if the patient returns to CMHDD. 
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Other important predictor variables are defined as the following: 
• Gender is a predictor variable classified into two categories as male and 
female; 
• Age is a continuous variable in year. It was classified by age group as 
categorical variable for analysis; 
• Marital Status is a categorical variable classified as single, married, 
widowed, separated, co-habiting; 
• Level of education is defined as no education, primary school, secondary 
school, university and Post University; 
• Living Situation is categorized as homeless, living with partner, living 
with parent and living with NGO partner; 
• Job was defined as categorical variable as no job, part time work, full time 
work that the patients had at entry point when they enrolled in the 
treatment; 
• History of opiates use is a continuous variable and referred to the past 
history of opiates use when the patients started to use opiates until the time 
of admission in MMT; 
• Frequency of Opiates use per week before enrolled in the treatment was a 
continuous variable and converted to categorical variables for analysis; 
• Pattern of drug use was categorized as Only Opiates Use, or Use Opiates 
with other illicit drug, smoking use or injecting use;  
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• Distance to clinic is a continuous variable and determined a distance from 
their living location to MT clinic. It was categorized into categorical 
variable for analysis; 
• Duration in MMT programme was referred to the duration of the patients 
enrolled in MMT during the period of this study and categorized in 
different groups of duration as categorical variables for analysis, 
• Methadone dose was referred to the maximum dose of methadone that the 
patients received during the period of the study. 
3.2 Methods 
3.2.1 Study Site 
The study was conducted at the Center for Mental Health and Drug Dependence 
in Phnom Penh, Cambodia. This center is the first center in Cambodia where the 
MMT has been established to provide treatment for Opiates Dependents. 
3.2.2 Selection (inclusion) Criteria 
• Must be adult patient 
• Can give consent 
• Patient needs to fulfill ICD-10 criteria (International Classification of 
Disease version 10). A definite diagnosis of dependence should usually be 
made only if three or more of the following have been present together at 
some time during the previous year: 
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o A strong desire or sense of compulsion to take the substance; 
difficulties in controlling substance-taking behaviour in terms of its 
onset, termination, or levels of use; 
o A physiological withdrawal state when substance use has ceased or 
been reduced, as evidenced by the characteristic withdrawal 
syndrome for the substance; or the use of the same (or a closely 
related) substance with the intention of relieving or avoiding 
withdrawal symptoms; 
o Evidence of tolerance, such that increased doses of the 
psychoactive substances are required in order to achieve effects 
originally produced by lower doses (clear examples of this are 
found in alcohol- and opiate-dependent individuals who may take 
daily doses sufficient to incapacitate or kill non-tolerant users); 
o Progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to 
obtain or take the substance or to recover from its effects; 
o Persisting substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive 
drinking, depressive mood states consequent to periods of heavy 
substance use, or drug-related impairment of cognitive functioning; 
efforts should be made to determine that the user was actually, or 
could be expected to be aware of the nature and extent of the harm. 
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3.2.3 Exclusion Criteria 
• Psychotic patient; 
• Negative Urine Test for Heroin Use; 
• Cannot communicate in Khmer; 
• Foreigner. 
• Severely sick because of other physical illness. 
• Without NGOs’ referral 
3.2.4 Data Collection Procedure 
A-Patient Enrollment and Treatment Process 
First, the patients need to meet a receptionist for registration and completing an 
informed consent form. Then they were referred to case managers and gave an 
interview for screening and assessment of psychosocial and substance abuse 
problems. After that the case managers were referred to doctors for final 
assessment. After seeing doctors, the patients were referred to primary health care 
nurses for blood and urine test. Finally the patients can get methadone dose at the 
pharmacy. 
All information given by the patients, and the results from screening, assessment 
and medical examination were recorded in MMT data management system. The 
patients were tracked from the enrollment until they dropped out of the treatment.  
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In case of dropout, the interviewers contacted NGOs partners or traced the 
patients in community to find out other information related to dropout. 
 
 
B- Materials 
The study used the data recorded in the MMT data management system that was 
completed by receptionist, case managers, doctors and pharmacists. There were a 
number of information items that were extracted for this study, such as: 
• Socio demographic information;  
• Patterns and types of Opiates Use; 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Receptionist: 
Registration 
Case Manager: 
Screening and 
Assessment 
Doctor: Diagnistic 
Formualtion 
Primary Health Care 
Nurse: 
Primary care, Blood and 
Urine Testing 
Pharmacist: 
Methadone Dosing 
Figure 3.2.4. 1: Flow of the patients and treatment process 
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• History of drug use; 
• Length of retention in MMT; 
• Distance to MMT clinic 
• Retention or non retention in Treatment; 
• Methadone dose for each patient 
3.2.5 Data Analysis 
The data was extracted from the MMT data management system of CMHDD and 
analyzed by using the SPSS version 16. The socio-demographic characteristics 
such as age, gender, educational level, marital status, job status, and living 
arrangement were described to identify the minimum, median, mean, maximum 
and percentage. The association between Independent variables (Sex, Age, Level 
of Education, Job Status, Age, Past history of Drug Use, Duration of methadone 
treatment and Methadone dose and Dependent variables (Retention or Non 
retention) was tested by using the chi-square test; T-student test; regression and p 
value of less than or equal to 0.05, to find out statistical significance. In 
application of statistical tests, 2 by 2 tables were made, then continuous variables 
were categorized as Yes/No or in categories: 
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• Age is a continuous variable, converted to  
 Variable Recode 
Age Group 18 – 23 Years old 0 
 24 – 29 Years old 1 
 30 – 35 Years old 2 
 36 – 41 Years old 3 
 Over 42 Years old 4 
 
• Length in treatment is a continuous variable, converted to 
Variable Recode 
Less than 1 year 0 
More than 1 year 1 
 
• Methadone dose is a continuous variable, converted to 
Variable Recode 
Methadone dose equal or lower than 60 mg/day 0 
Methadone dose over 60 mg/day 1 
 
• Distance to MMT clinic is a continuous variable, converted to 
Variable Recode 
Equal or shorter than 4 km 0 
More than 4 km 1 
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• Past history of Opiates use before MMT is a continuous variable, 
converted to 
Variable Recode 
Less than or equal to 3 years 0 
From 4 to 6 years 1 
From 7 to 9 years 2 
More than 9 years 3 
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CHAPTER IV 
4- RESULTS 
The enrollment of the patients started from 1 July 2010 to 30 June 2011. There 
was an interruption to the enrollment between October 2010 and February 2011 
due to a lack of incentive supports for MMT staff. Totally there were 107 patients 
enrolled in the treatment. All of them were referred by NGOs partners such as 
Korsang Organization and Kalyan Mitt organization. All the enrolled patients 
were followed until 30 September 2011. The patients enrolled in this study had 
different duration of treatment in MMT due to different times of enrollment. The 
groups of cohort varied from 4 months to 15 months. It was noted that 4 patients 
were dead so, they were excluded from this study. Therefore, 103 patients were 
included in the analysis, where 83 patients were male and 20 were female. Table 
5.0.1 summarizes the number of MMT patients who enrolled in the study by 
month. 
Table 4.0. 1: Number of MMT patients enrolled by month 
Time of enrollment Number of Patients Cohort time 
July 2010 22 15 Months 
August 2010 27 14 Months 
September 2010 12 13 Months 
October 2010 0  
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November 2010 0  
December 2010 0  
January 2011 0  
February 2011 0  
Mach 2011 14 7 Months 
April 2011 05 6 Months 
May 2011 19 5 Months 
June 2011 08 4 Months 
 
The table 4.0.1 shows that 22 patients were followed up for 15 months and 107 
patients had 4 months of follow up. 
Figure 4.0. 1: Cumulative new patients enrolled in MMT during the period of 
12 months 
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Figure 4.0. 2: Percentage of Overall Retention 
 
In this cohort study, it is shown that the retention rate is high compared to other 
studies. However, originally 103 patients were enrolled in this analysis in the 
treatment in different times over the period of this cohort. Looking at the retention 
rate within up to 3 months in treatment, there were 92.2% (N = 95). Up to             
6 months, 9 months, 12 months, and 15 months, the retention rates were 
respectively 80.2% (N = 57), 72.4% (N = 42) and 70.7% (N = 41) and 70.7%     
(N = 41).  The table 4.0.3 shows a comparison of Retention in MMT done by 
other studies. 
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Table 4.0. 2: Number of patients in different cohort time 
Cohort time Number of patients enrolled in cohort Retention in Cohort 
3 months 103 95 
6 months 71 57 
9 months 58 42 
12 months 58 41 
15 months 58 41 
Table 4.0. 3: Comparison of Retention Rate with other Studies 
 
Einat et 
al. 
Peymaneh 
et al. 
Sharifa W.P 
et al. 
Enwu Liu 
et al. 
Mohamad 
Nasir et al. 
Duration 10 years 6 months 3 months 14 months 6 months 
Design Cohort Cohort 
Cross 
sectional 
Cohort Cohort 
Sample  492 282 288 1003 64 
Country  Israel Iran Malaysia China Malaysia 
Retention 
74.4% 22.7% 86.1% 56.2% 54.6% 
1 year 
retention 
6 month 
retention 
3 month 
retention 
14 month 
retention 
6 month 
retention 
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Figure 4.0. 3: Retention at different lengths in treatment in the cohort 
 
4.1 Demographic Characteristics 
There were 103 patients enrolled in the treatment from 1 July 2010 to 30 June 
2011. The majority of participants were males (N: 83), which were accountable 
for 81%, and 19% were females (N: 20).  
Table 4.1. 1: Demographic Characteristics 
Variables Number Percentage 
Sex   
Male 83 80.6 
Female 20 19.4 
Age (Mean: 30, Median: 30)   
18 - 23 Years 15 14.6 
24 - 29 Years 43 41.7 
92.2% 
80.2% 
72.4% 70.7% 70.7% 
0% 
20% 
40% 
60% 
80% 
100% 
3 month 
retention 
6 month 
retention 
9 month 
retention 
12 month 
retention 
15 month 
retention 
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30 - 35 Years 30 29.1 
36 – 41 Years 07 06.8 
Over 42 08 07.8 
Marital Status   
Single 42 40.8 
Married 39 37.9 
Divorced 12 11.7 
Widowed 03 02.9 
Separated 02 01.9 
Cohabiting 05 04.9 
Education   
No education 20 19.4 
Primary School 37 35.9 
Secondary School 45 43.7 
University and Higher 01 01.0 
 
Among the male (N = 83) and female patients (N = 20), 81.9% and 85% were 
retained to do the treatment, respectively. It was shown that female patients had 
higher retention rate compared to male (85% vs. 82%) but there was no statistical 
significance (Chi = 0.105, df = 1, p = 0.74).  
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Table 4.1.2: Gender and Retention 
Variables Retention Non retention 
Male 68 (82.0%) 15 (18.0%) 
Female 17 (85%) 03 (15.0%) 
Chi = 0.105, df = 1, p = 0.74 
 
The age group varied from 18 years old to 52 years old (Total mean of age: 30 
years, median: 29 years). The mean of age among females is higher than male 
(Age Mean of male: 29 years, median age of male: 28.5 years, Age Mean of 
female: 32 years, median age of female: 29 years). The results also showed that 
the younger age and older age had lower retention rate. In this study, retention rate 
of groups of patients aged lower than 23 years (73%) or higher than 36 years     
(71%, 63%) was lower compared with retention rates of groups of patients aged 
between 24 years to 35 years (87%, 88%). However, statistically there was no 
significant association between retention and age group. Compared with studies 
done by Sharifa WP et al., (2009) and Carol J. et al., (2005), this study found 
different results. In their studies, older age was associated with higher retention 
rates. 
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Figure 4.1. 1: Histogram of Age (in Years) 
 
Table 4.1. 3: Age and Retention 
 Variables Retention Non retention 
Age From 18 to 23 Years 11 4 
From 24 to 29 Years 38 5 
From 30 to 35 Years 26 4 
From 36 to 41 Years 5 2 
Over 42 Years old 5 3 
 Chi = 5.7,df = 4, p = 0.27 
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Most of them were single (N = 42, 40.8%) and married (N = 39, 37.9%), divorced 
(N = 12, 11.7%), widowed (N = 3, 2.9%), separated (N = 2, 1.9%) and cohabiting 
(N = 5, 4.9%). The group of patients who were married (N = 39) had high 
retention (90%) compared to other variables such as single, widowed, and 
divorced who had 81%, 75%, and 33% retention, respectively. However, there 
was no significant association between marital status and retention (Chi = 7.43,  
df = 5, p = 0.19). 
Table 4.1.4: Marital Status and Retention 
Variables Retention Non retention 
Single  34 08 
Married 35 04 
Divorced 09 03 
Widowed 01 02 
Separated 02 00 
Co-habiting 04 01 
Chi = 7.43, df = 5, p = 0.19 
 
According to this study, the majority of patients had low education, where 19.4 % 
of them had no education (N = 20) and 35.9% were at primary school (N = 37); 
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Junior High school, High School and University were respectively accountable for 
26.2% (N = 27), 17.5% (N = 18) and 1% (N = 1). 
The group of patients with primary school or lower education (N = 57) had a 
lower retention rate (81%) compared to higher education (85%). However, in this 
study there was no significant association (Chi = 0.294, df = 1, P = 0.59). 
Table 4.1.5: Education and Retention 
Variables Retention Non retention 
Primary school or Lower education 46 11 
Higher than Primary school education 39 07 
Chi = 0.294, df = 1, p = 0.59 
4.2 Social Characteristics 
Table 4.2. 1: Social Characteristics 
Variables Number of enrolled patients Percentage 
Job Status   
Currently not work 67 65.0 
Currently Self-employed 17 16.5 
Currently work part time 08 10.7 
Currently work full time 11 10.7 
42 
 
Living Arrangement   
Homeless 08 07.8 
Living with partner 13 12.6 
Living with parent 27 26.2 
Living in NGO facility 42 40.8 
Others 13 12.6 
Distance to Clinic   
Up to 4 Km 71 68.9 
From 5 to 15 Km 32 31.1 
Most of the enrolled patients (65.0%) had no job (N = 67); the self-employed, and 
those with part-time, and full-time job were respectively 16.5% (N = 17), 7.8%  
(N = 08), and 10.7% (N = 11). Compared with other variables, No job had higher 
retention rate (N = 56, 83.5%) than other groups (N = 29, 80.6%) such as any job 
either self employed or part-time or full time job. However, in this study there was 
no significant association between job and treatment retention (Chi = 0.149,        
df = 1, P = 0.7). 
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Table 4.2.  2: Job and Retention 
Variables Retention Non retention 
No Job 56 11 
Any Job 29 07 
Chi = 0.149, df = 1, p = 0.7 
 
According to the study done by Yanhua Che et al. (2011), this study is shown up 
differently. Patients who were unemployed tend to attend the clinic for treatment 
more frequently compared to employed patients. Similar studies, Jose et al. (1977) 
revealed that the patients who were employed at the time of admission have 
consistently been more successful than unemployed. Pam Franscis et al. reported 
in an evaluation of Methadone Maintenance Treatment Services that Clients with 
poor employment records have had poor retention rates in methadone treatment 
programmes compared to clients with more successful employment records. 
However, Mitchell et al. (2005) revealed that employment has no significant 
relation with retention. There is only an indication that the employed, full-time / 
part-time, tend to stay longer than the unemployed.  
Regarding to housing situation, the majority of MMT patients had no stable 
housing. That means about 7.8% (N = 08) were homeless, 26.2% (N = 27) were 
living with parents, and about 40.8% (N = 42) with NGO facilities, 12.6%           
(N = 16) with partners. This study has shown that the patients who lived with 
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partners (N = 13) had lower retention rate (54%) compared to other groups. 
Statistically, it revealed that there was a significant association between retention 
and living situation. It is also shown that the Group of homeless, living in NGOs 
facility and living with parents have higher retention rates whereas a group of 
patients who lived with partners had a lower retention rate (Chi = 13.83, df = 4,    
p = 0.008). 
This finding appeared differently with Lundgren Lena M. (2007), who found that 
Homeless patients had lower retention rates compared to a group of patients who 
were not homeless. However, this is probably because the group of homeless 
patients in this study got more support from outreach NGOs working in 
Community. 
Table 4.2.  3: Living Situation and Retention 
Variables Retention Non retention 
Homeless 8 0 
Living with partners 7 6 
Living with parent 22 5 
Living in NGOs facility 39 3 
Others 9 4 
Chi = 13.83, df = 4, p = 0.008 
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The distance from their living locations to MMT clinic varies from less than 1 km 
to 15 km (mean = 4.45, median = 4, SD = 2). 71 patients (68.9 %) in this study 
lived within an equal distance to or less than 4 Km from the clinic, and 32 patients 
lived in locations further than 4 km. 
In this study, it was shown that the further distance to MMT clinic, the higher 
retention rate. That means 78.8 % of a group of patients living within 4 km from 
the clinic retain in treatment, and the retention rate among a group of patients 
living further than 4 km was 90.6% (N = 29). But, there is no statistical 
significance. However, it shows contrast with some studies (Peymaneh, 2009; 
Riza, 2009), which showed that the shorter distance to MMT clinic, the better 
retention rate in MMT. This finding reflects the important roles of NGOs working 
in community which can help MMT programme in supporting the patients to 
access MMT clinic. 
Table 4.2.  4: Distance to MMT Clinic and Retention 
Variables Retention Non retention 
Equal or shorter than 4 Km 56 15 
More than 4 Km 29 03 
Chi = 2.11, df = 1, p = 0.146 
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Figure 4.2. 1: Histogram of Distance to Clinic (in Kilometers) 
 
 
Among 103 patients in this study, 52 patients (50%) had partners who were not 
drug user, and the other 51 patients had a partner who was drug user. The patients 
whose partners were also drug users (N = 51) had lower retention rates (N = 41, 
80.3%) compared to the patients whose partners were not drug users (N = 44, 
84.6%). However, there was no significant association between the two variables 
(Chi = 3.18, df = 1, P = 0.57). 
4.3 History, Patterns and Types of Drug Use 
There were different histories of Opiates use; the history of opiates use varied 
from less than one year to 45 years (Mean: 9.8 and median: 8). However, few of 
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them had used Opiates more than 10 years before attending at MMT. Among the 
patients enrolled in this study, female patients had a longer history of heroin use 
compared to male patients (Mean of year for female: 13, median of year for 
female: 9 years; Mean of year for male: 9 years, median of year for male: 7.5 
years). In this study no correlation was shown between history of opiates use and 
retention. Soyka et al., (2008) found that the duration of continuous opioid use 
and the age at onset of opiates dependence were found to have a predictive value 
for negative outcome. 
Figure 4.3. 1: Histogram of Past History of Opiate Use (in Year) 
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Table 4.3.  1: History of Opiate Use and Retention 
Variables Retention Non Retention 
Past History of Opiates Use before MMT   
Less than or equal to 3 years 20 03 
From 4 to 6 years 18 05 
From 7 to 9 years 19 03 
More than 9 years 28 07 
Chi = 0.93, df = 3, p = 0.82 
Table 4.3.2 shows patterns and types of drug use. 103 patients were Opiates users. 
Most of them used Opiates and other drugs (N = 94, 91.3%), only 9 patients were 
single opiate users (08.7%). This study showed that patients who used heroin and 
other drugs (N = 94) had lower retention rate (N = 76, 81%). Statistically, there 
was no significant association (Chi = 2, df = 1, p = 0.14). 
Within this sample, the majority of the patients were Injecting Drug Users, which 
were accountable for 93.2% (N = 96), and only 07 patients were Opiates smokers 
(6.8 %). The group of patients who injected drug had higher retention rate (83%) 
compared with retention rate among a group who smoked drugs (71%). In this 
study, there was no significant association between patterns of opiates use and 
treatment retention.  
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Table 4.3.  2: Patterns and Types of Drug Use 
Variables Number Percentage 
Main Route of Opiates use   
Injection 96 93.2 
Smoke 07 6.8 
Types of Drugs Use   
Opiates Use Only 09 8.7 
Opiates and Others 94 91.3 
 
Table 4.3.  3: Main Route of Opiate Use and Retention 
Variables Retention Non Retention 
Main route of opiate use   
Injection 80 16 
Smoke 05 02 
(Chi = 0.6, df = 1, p = 0.42) 
Of 103 patients, the frequency of opiates use varied from 7 to 56 times per week 
(Mean: 26, Median = 28. SD = 9.8). That means in average, they used opiates 
more than 3 times a day. 52.4 % of them used opiates more than 4 times a day. 
Retention rate among patients who used opiates less than 4 times a day (78%) was 
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lower than those who used drug more than 4 times a day (87%). Table 4.3.5 
shows the frequency of opiates use per day and retention. 
Table 4.3.4: Frequency of Opiate Use 
Figure 4.3. 2: Histogram of Frequency of Opiate Use 
 
  
Variables Number Percentage 
Used Opiates less than 4 times a day 49 47.6 
Used Opiates more than 4 times a day 54 52.4 
 (Range: (7 - 56), Mean: 26, Median: 28, SD = 9.8) 
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Table 4.3.  5: Frequency of Opiate Use and Retention 
Variables Retention Non Retention 
Frequency of opiate use   
Used Opiates Less than 4 times a day 38 11 
Used Opiates from 4 times a day and more 47 07 
(Chi = 1.6, df = 1, p = 0.2) 
4.4 Methadone Treatment and Retention 
1. Length in MMT treatment 
Among 103 patients, 57.3% (N = 59) had a length of stay in MMT less than one 
year, and 42.7% (N = 44) had more than one year. Retention rate among the 
patients who attended in MMT less than one year was 69.4% (N = 59). The 
retention rate among the patients who received MMT less than one year was 
lower than the rate among patients who retained in treatment more than one year. 
Table 4.4.1 shows the length in MMT and retention: 
Table 4.4.1.1: Length in MMT 
Variables Number Percentage 
Length in MMT Treatment   
Less than one Year 59 57.3 
More than one year 44 42.7 
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Table 4.4.1.2: Comparison between Length in MMT and Retention 
Variables Retention Non Retention 
Length in MMT   
Length in MMT less than one year 41 18 
Length in MMT more than one year 44 00 
2. Methadone dose 
Usually the initial dose of methadone was 20mg. Every 3 or 5 days, 5mg of 
methadone was increased based on the judgment of a doctor. The increment of 
methadone gradually increased until the patients had no withdrawal symptoms. In 
this study, the maximum dose of methadone varied from 20mg to 120mg      
(Mean = 74.6, Median = 70, SD = 22). 
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Figure 4.4. 1: Gradually Methadone Dosing Process 
 
Source: Center for Mental Health and Drug Dependence in Cambodia, 2010 
However, the increment of methadone was dependent on the patients’ compliance 
and therapist’s judgment. That means, in principle, if the patients missed the 
methadone dose between 3 to 5 consecutive days, the methadone was reduced by 
half. So in some cases, they missed doses so often so that their doses could not be 
increased and remained low compared to others patients who regularly took 
methadone doses.  
In this sample, it was found that 34% (N = 35) of the patients got a average daily 
methadone dose equal to or less than 60mg, and the other 66% (N = 68) received 
average daily methadone dose more than 60mg. 
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Figure 4.4. 2: Histogram of Methadone Dose (in Milligrams) 
 
 
Table 4.4. 2.1: Methadone Dose Comparison 
Variables Number Percentage 
Average Daily Methadone Dose   
Less than or equal to 60mg 35 34.0 
More than 60mg 68 66.0 
(Chi = 4.52, df = 1, P = 0.03)   
 
Comparing between the patients who received over 60mg of methadone dose per 
day and those who received methadone dose equal or lower than 60mg per day, it 
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was found that the retention rate of the patients who got methadone dose more 
than 60 mg/day was higher. Statistically, there was a significant association     
(Chi = 4.52, df = 1, P = 0.03). 
Table 4.4.2.2: Retention and Methadone Dose 
Variables Retention Non Retention 
Methadone dose equal or lower than 60 mg/day 25 10 
Methadone dose Over 60 mg/day 60 08 
  Chi = 4.52, df = 1, P = 0.03 
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CHAPTER V 
 
5- DISCUSSION 
This study tried to explore factors associated with Retention in MMT among the 
patients receiving a Methadone dose at the Center for Mental Health and Drug 
Dependence (CMHDD). In Cambodia there is only one center for treatment of 
Opiate dependents, which is located in the Capital where most of opiate 
dependents living.  The capacity of the clinicis for about 250 to 300 patients only. 
Based on Expert consensus, there are about 1,000 to 10,000 heroin users in 
Cambodia; it is seen that the MMT clinic cannot respond to the needs of Opiates 
users in Community. That means the supply side is not adequate for demand side. 
Moreover, as CMHDD is just newly established, the center could only get patients 
referred by NGOs partners. It is due to the fact that the center needs to assure 
follow up and linkage between MMT clinic and community within its limited 
capacity. In this regard, it is obvious that the operating system is limited and not 
with free access, that means only the patients who were referred by NGOs 
partners can access to MMT clinic. Usually NGOs work with vulnerable 
populations such as the homeless and jobless population. So the population in this 
study does not represent the general population of opiate users. 
5-1 Retention in Methadone Maintenance Therapy 
In this study, it was shown that the retention rates are different at different cohort 
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time. The retention rates were respectively 92.2% for 3 months retention, 80.2% 
for 6 months, 72.4% for 9 months and 70.7% for 12 months. These rates were 
high compared with other MMT programmes in the region. In Malaysia, Nasir 
Mohamad et al., (2010) found that 6 months retention was about 54.69%. In a 6 
months cohort study in MMT programme conducted in Indonesia, they found that 
the 3- and 6-month retention rates were respectively 74.2% and 61.3% (Riza, 
2009).  
In China, Liang et al., (2009), in a 14 month cohort study in 8 locations, they 
revealed that the 6 month retention rate of the clients was 68.8%, and 57.4% at 12 
month of the treatment programme. It is difficult to conclude about the different 
rates of retention comparing with those studies, because in different countries, 
there are different contexts in terms of socio-economic and political contexts and 
service arrangement and delivery system. 
However, the diversity contexts of MMT service organization would be taken into 
consideration. In this regard current MMT service in Cambodia was free of charge 
and operated in collaboration with NGOs working community, which were the 
main supporters in referring and following up the patients in community.  
Moreover, most of the participants in this sample were a marginalized population 
and could not represent the general population of opiates users. As they were a 
vulnerable population, usually they got more supports from NGOs working in 
community. 
58 
 
MMT is a long-term treatment. Very often the patients attending a long-term 
treatment could not retain in as long as the duration of treatment, and retention 
rate fell lower along the way. In this study, the retention rate is decreasing from 
92.2% to 70.7% from 3 month retention to 15 month retention. However, in the 
group of non-retention patients most of them quitted the treatment at an earlier 
stage of treatment. Among 18 patients who did not retain in MMT, it was found 
that 44% (N = 8) quitted the treatment within the first 3 months. And respectively, 
there were 33% (N = 6), 17% (N = 3), and 6% (N = 1) within the period of           
6 months, 9 months and 12 months. Miguel et al., (1997) found that the dropout 
rate among MMT patient was higher during the first and second year of treatment, 
compared to the subsequent year. This may be due to the early stage of treatment; 
the patients were difficult to cope with withdrawal symptoms while their 
methadone dose needs to be adjusted with their tolerance and withdrawal 
symptoms. 
Figure 5.1. 1: Number of Non-Retention by Time 
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5-2 Retention and Socio-Demographics 
This study found that predictive variables such as gender, age, marital status, job 
and level of education were not associated with retention in MMT treatment. In 
this study, gender was not associated with retention. Retention among males was 
lower than among females; 82% (N = 68) for males and 85% (N = 17) for 
females. In this regard, Female Drug Users were usually considered a vulnerable 
group; they could get support from NGOs more than males in terms of contact, 
reminding, and facilitation. However, Rizar (2009) stated that in many studies, 
there was no consistency association between gender and retention. Some studies 
show males had higher retention rate while other studies found a reverse situation. 
Table 5.2.1: Chi-square test between Gender and Retention 
Gender 
Compliance 
P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
 
Male 
68 
(82%) 
15 
(18%) 
0.745 
Female 
17 
(85%) 
3 
(15%) 
In this study, there was no association between age and retention. In this sample, 
the mean and median of age were 29 years and 29.8 years. There was no 
difference between the mean and median of retention and non retention groups. In 
the results of this study, the younger group (aged from 18 to 23 years) and the 
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older group (aged from 36 years) had lower retention rates compared with a group 
aged from 24 to 35 years old. It was contradictory to other studies, which found 
that older age had longer retention in treatment.  
Davis C. et al., (2006) found that Age over 40 years had a significant association 
with MMT retention. Similarly Einat et al., (2006) showed that Age equal to or 
over 40 years was associated with a cumulative longer retention in MMT 
treatment. Dannis et al., (2005) revealed that older patients had a higher retention 
rate in MMT. However, mean age of the sample in this study showed that the 
population of this study was younger (mean = 29 years) compared to population 
of those studies.  
Table 5.2.2: Chi-square test between Age Group and Retention 
Age 
Compliance 
P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
(%) 
18 - 23 Years Old 11 
(73.3%) 
4 
(26.7%) 
0.279 
24 - 29 Years Old 38 
(88.4%) 
5 
(11.6%) 
30 - 35 Years Old 26 
(86.7%) 
4 
(13.3%) 
36 - 42 Years Old 5 
(71.4%) 
2 
(28.6%) 
Over 42 Years Old 5 
(62.5%) 
3 
(37.5%) 
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Many studies found that Job is associated with retention in MMT treatment 
(Herman et al., 2000) but it was not found in this study. This may be because most 
of respondents in this study had no sustainable job. It is due to the fact that they 
are marginalized population. In this regard, even though they have full time job, 
their jobs would not be a sustainable job, as well as low skill jobs. So there is still 
no difference between jobless and fulltime job because even in those with a full 
time job, it was not a sustainable job, and their incomes would not be a significant 
difference too. They still rely on NGOs supports to access to MMT clinic. In this 
study, among jobless patients the vulnerable group and got more supports from 
NGOs, so they could retain better in treatment.  
Table 5.2.3: Chi square test between Job Status and Retention 
Job Status 
Compliance 
P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
(%) 
No Job 
56 
(83.6%) 
11 
(16.4%) 
0.149 
Any Job 
29 
(80.6%) 
7 
(19.4%) 
 
The overall duration of history of opiate use in this sample varied from 12 to 42 
years with a mean of 22.6 and median of 29 years. There was a similarity between 
the mean and median of retention and Non-retention group (Retention, Mean: 22 
years, Median: 22 years; Non retention, Mean: 23.8 years, Median: 22 years). In 
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this study, duration of history of opiate use was split into 4 categories such as up 
to 3 years, from 4 to 6 years, from 7 to 9 years, and over 9 years. Statistically 
there was no association between history of opiate use and treatment retention    
(p = 0.82). Miguel et al., 1997 revealed that the history of opioid use is a 
predictive factor of treatment retention that means shorter duration of opiates use 
had shorter rates of retention. Sharifa et al., (2009) found that the shorter duration 
of addiction showed a good compliance in MMT.  
Table 5.2.4: Chi square test between Past History of Opiate Use and 
Retention 
Past History of 
Opiates use 
Compliance 
P-value  
(Chi square test) Retention 
(%) 
Non Retention 
(%) 
Less than or 
equal to 3 years 
20 
(87) 
3 
(13) 
0.805 
4-6 years 
18 
(78.3) 
5 
(21.7) 
7-9 years 
19 
(86.4) 
3 
(13.4) 
More than 9 
years 
28 
(80) 
7 
(20) 
Distance to clinic is also a factor of accessibility; in this study, the distance varied 
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from 1 to 15 km with a mean of 4.45 km and median of 4 km. Comparing 
between a group of patients living equal to or less than 4 km and over 4 km, there 
was no significant association between distance to clinic and treatment retention   
p = 0.146). Peymaneh Shirinbayan, 2009 and Riza Saravita 2009 found distance 
to clinic as a predictive factor of treatment retention; the shorter distance to clinic, 
the higher treatment retention. It was reflected that the patients in this study got 
transportation support from NGOs at least during the first 3 months of treatment 
especially during induction phase. After the induction phase, NGOs could support 
vulnerable groups who really needed transportation. This context may be different 
from other MMT services.  
Table 5.2.5: Chi square test between Distance to MMT clinic and Retention 
Distance to MMT 
Clinic 
Compliance 
P-value  
(Chi square test) Retention 
(%) 
Non Retention 
(%) 
0-4 Km 56 
(79) 
15 
(21) 0.146 
Over 4 Km 29 
(91) 
3 
(9) 
Many studies showed that the homeless were also associated with higher 
retention. Compared with non-homeless patients, a group of homeless patients had 
lower retention rate (Lundgren, 2007). 
However, our study showed that homeless, living in NGOs facilities and living 
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with parents had significantly higher retention. 
This is due to NGOs supports. It is due to the fact that those patients were a most 
at risk population and vulnerable groups so they got more support from NGOs 
than other groups. 
Table 5.2.6: Chi square test between Living Situation and Retention 
Living Situation 
Compliance P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
(%) 
Homeless 8 
(100) 
0 
(0) 
0.008 
Living with 
partner 
7 
(53.8) 
6 
(46.2) 
Living with 
parent 
22 
(81.5) 
5 
(18.5) 
Living in NGO 
facility 
39 
(93) 
3 
(7) 
Other 9 
(69.2) 
4 
(30.8) 
5-3 Retention and Patterns of Opiate use 
Patterns of Opiates use in this study were injecting and smoking use. Among 103 
patients, 93.2 % of them (N = 96) were injecting drug users and 6.8% were 
smoking user (N = 7). It would highly increase the risk to be infected by blood 
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borne diseases when they shared needle and syringe. The injecting opiates users 
had higher retention rate compared to Smoking opiates user. In our study, there 
was no association between route of opiates use and retention (p = 0.42). 
Table 5.2.7: Chi square test between Main Route of Opiate Use and 
Retention 
Main Route of 
Opiates Use 
Compliance P-value  
(Chi square test) Retention 
(%) 
Non Retention 
(%) 
Injection 80 
(83.3) 
16 
(16.7)  
0.423 Smoking 5 
(71.4) 
2 
(28.6) 
Regarding types of drug use in our study, the majority of the patients (N = 94, 
91.3 %) used opiates and other substances in addition. A group of patients who 
used more opiates had lower retention rate compared to a group of single opiates 
use.  
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Table 5.2.8: Chi square test between Types of Drug Use and Retention 
Types of Drug 
Use 
Compliance P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
(%) 
Only Opiates Use 9 
(100) 
0 
(0)  
0.148 
Opiates use and 
Other  
76 
(81) 
18 
(9) 
Frequency of drug use was not found its association with retention in MMT 
treatment. This study found that a use opiates less than 4 times a day had lower 
retention rate.  
Table 5.2.9: Chi square test between Frequency of Opiate Use and Retention 
Frequency of 
Opiates Use 
Compliance P-value  
(Chi square test) 
Retention 
(%) 
Non Retention 
(%) 
Less than 4 times 
a day 
38 
(77.6) 
11 
(22.4)  
0.205 
Use Opiates from 
4 times a day or 
more  
47 
(87) 
7 
(13) 
5-4 Retention and Methadone Dose 
Many studies found a significant association between Methadone Dose and 
treatment retention (Liu et al., 2008, WHO, 2004, Bao et al., 2009).
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Looking at Methadone dose in this study, it was shown that the maximum daily 
individual dose of methadone varied from 20mg to 120mg and the average dose 
of methadone among the participants were 70 mg/person/day. But the average 
dose of retention group was from 30mg to 115mg (Mean = 76.3 mg,             
median = 70 mg, SD = 18.9); its mean was higher than the dose of non-retention 
group     (Mean = 66.3 mg, median = 60 mg, SD = 31.7). This study found that the 
dose over 60 mg/person/day was significantly associated with treatment retention   
(p = 0.03). This finding is parallel with other findings, which indicated that higher 
methadone dose was associated with retention. 
WHO, (2004) recommended that a dose of methadone over 60 mg/day/person had 
clear association with treatment retention and could suppress heroin use. Similarly 
it was found that Methadone doses from 60mg to 100 mg/day were considered as 
effective MMT (NIDA, 2003). An expert panel at the National Institute of Health 
also found that the dose of methadone at least 60mg was considered as the best 
practice in methadone maintenance therapy (Thomas et al., 2005). 
Yanhua Che et al., (2010) found that there was no relationship between dose and 
probability of dropout in periods 1 and 3 months. However, after 3 month, there 
was lower a probability of dropout with higher average daily dose > 60 mg. 
A study in China found that dose of methadone equal to and higher than 60 mg 
had higher retention rate compared to a group of patients who had methadone 
dose lower than 60 mg per day per individual (Bao et al., 2009). 
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Table 5.2.10: Chi square test between Methadone Dose and Retention 
Average Daily Methadone Dose Retention 
(%) 
Non 
Retention 
(%) 
P-Value  
Chi-square 
Test 
Methadone Dose Less than or 
equal to 60 mg 
25 
(71.4) 
10 
(28.6) 
 
0.033 
Methadone Dose more than 60 mg 60 
(88.2) 
8 
(11.8) 
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CHAPTER VI 
 
6- CONCLUSIONS AND LIMITATIONS 
6.1 Conclusions 
Methadone Maintenance Therapy has been established since 2010; it can attract 
many opiate users to treatment. Retention rate of MMT in Cambodia is very 
similar to other studies found in various MMT services. The overall retention rate 
were 82.5%. Looking at different times in the cohort, it was shown that the 
retention rate within the cohort of 3 months, 6 months, 9 months, 12 months and 
15 months was 92.2%, 80.3%, 72.4%, 70.7% and 70.7%, respectively. 
In this study, among demographic characteristics and social factors through 
methadone dosing within the 15 month cohort, it was found that gender, age, 
marital status, level of education, job, history of opiates use, and distance to clinic 
were not associated with retention in treatment.  
Living situation and methadone were found association with retention in MMT. A 
group of patients who had unstable housing (homeless, living with parent, living 
in NGOs facility) had higher retention rate with statistical significance                 
(p = 0.0001). However, the population in this study could not represent general 
population of MMT clients because the population in this sample was at risk 
group needing support from NGOs. Its higher retention may be due to the fact that 
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those groups of patient were vulnerable and got assistance from NGOs who 
facilitated their access to MMT clinic.   
Methadone dose was also a predictor variable. In this clinic the mean of 
Methadone dose per day per individual was 70 mg. The dose of methadone equal 
to or over 60 mg/day was significantly associated with retention. This finding is 
supported by many studies and recommendations, which was showed that a dose 
of methadone over 60 mg/day is associated with treatment retention. 
In addition, it was also found that most of non-retention patients quitted their 
treatment during the early stage of treatment within the period of 3 to 6 months. 
This would be concluded that it is related to the methadone dosing process, which 
the patients received. Methadone dose is usually started from 20 mg and increased 
every 3 to 7 days until the patients have no craving to use opiates again. That is a 
reason that the patients quitted their treatment more at an early stage because of 
withdrawal symptoms and craving. However, WHO (2004) has recommended 
methadone dose delivered based on therapist’s judgment.  
The retention rate varied from 92.2% within the first 3 months of treatment to 
72.4% within 9 month cohort and 70.7% within 15 month cohort. It showed that 
the lower rate of patients quitted the treatment after 9 month in treatment.  
However, these findings could not be generalized to all opiate users because the 
sample in this study is relatively small. However, it could be used as baseline for 
further study in the future to explore the effectiveness of MMT. 
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These results showed that the MMT programme in Cambodia could be considered 
as an effective programme concerning reduction of harm related to opiates use 
and daily opiate use. Possible scale up of the programme to other area in the 
country should be encouraged. However, there are other influenced factors that 
this study does not focus on to ensure holistic perspectives in regard to treatment 
retention in MMT. 
A next study should explore other factors such as clients ‘perceptions or attitudes 
to MMT services, organization of MMT service, quality of life, co-morbidity with 
opiates dependence, intervention modalities including counseling and 
psychosocial interventions, and ancillary services. Those factors would be 
influential to reinforce the quality assurance of MMT service. 
Wang J. et al., (2007), in a study in China concluded that individual counseling 
could increase compliance rate among MMT patients in Urumqi. Similarly, 
Canada Health 2002 reported that Counseling could enhance MMT treatment 
retention and decrease opioid use (Canada’s Drug Strategy Health Canada, 2002). 
Perception of patients toward MMT is also important to retain the patients in 
MMT. In this regard, Thesis’s Liu (2009) found that patients who committed to be 
treated at MMT service for life who intended to be treated in the methadone clinic 
for life seem to stay longer in the treatment.  
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Fischer Benedikt et al., (2006) has recommended that effective treatment must 
adjust to poly substance use and address the complex co-morbidity physically and 
mentally among the at risk population. 
A national treatment agency for substance abuse in United Kingdom has reported 
that the effectiveness of methadone maintenance therapy depends more than just 
on methadone dose. A range of organizational management need to be arranged 
such as Counseling, other psychosocial interventions and ancillary services need 
to be provided to enhance outcome of methadone maintenance therapy (National 
Treatment Agency for Substance Misuse, 2004). WHO, UNODC, UNAIDS 
position paper 2004 showed that counseling and psychotherapy influence on the 
overall effectiveness of MMT. 
6.2 Limitations 
There are many limitations in this study. At this stage MMT service is not a free 
access service. The enrollment of MMT patients in the programme is strict. Most 
of the patients enrolled in this study were referred and supported by street based 
NGOs. Therefore, the sample of this study could not represent the general 
population of opiate users in a Community in which it was estimated that there are 
about 1.000 to 10.000 heroin users in Cambodia (NACD, 2007). Obviously, that 
this sample is relatively small compared with the estimated number. Moreover, 
the profiles of the patients enrolled in this study is low class population. There are 
patients from higher class population who do not disclose themselves for 
treatment. 
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Looking at predictive factors, there are other factors that this study did not focus 
on such as patients’ perception to MMT, co-morbidity, quality of life and quality 
of counseling and treatment. Those factors may be confounding factor for these 
findings. In addition, this study did not include a qualitative method to control for 
these findings. Not using regression and survival analysis is a limitation of this 
conclusion. 
It is also difficult to compare methadone maintenance therapy programme with 
other countries because the organization of methadone service considerably varies 
from one country to another. 
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APPENDIX  1: CONSENT FORM 
 
INFORMED CONSENT FOR VOLUNTARY METHADONE 
MAINTENANCE THERAPY 
 
MY NAME IS: ………………………………………..…… GENDER: …..…… 
 
DATE OF BIRTH (OR APPROXIMATED AGE): …………………………...… 
 
PLACE OF BIRTH (if known): 
 
 …………………………………………………………………………………….. 
 
ADDRESS:  
 
……………………………………………………………………………….......... 
 
REFERRED BY:  
 
………………………………………………………………………….................. 
 
CONTACT PERSON IN CASE OF EMERGENCY: 
 
 …………………………………………………………………………………..... 
 
PHONE NUMBER: ………………………………………….…………..……….. 
 
ADDRESS: 
………………………………………………………..…………………………..... 
 
 
After being informed about methadone treatment and about possible side effects 
that may occur during treatment, I understand the objectives of the treatment I 
shall receive. I confirm that I have read and understood the related important 
information which explains the objectives and risks of the treatment and have 
discussed it with a counselor / nurse at the clinic. I freely agree join the 
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methadone treatment programme and I therefore undertake: 
 
1. To comply with the regulations of the methadone treatment clinic and to 
attend regularly to collect methadone and to participate in the treatment 
and counseling programmes. 
2. To refrain as much as possible, from using any other substances of which 
may endanger and have serious consequences for my health during 
methadone treatment. I am fully aware of the risks of using alcohol and 
benzodiazepines, methamphetamines, heroin, morphine, opium while I am 
being prescribed methadone. 
3. To keep health professionals informed of emerging health and social 
issues so facilitate timely actions by the clinic staff. 
 
In case of any undesirable consequences that occur due to the failure to comply 
with the agreement I (and my family) shall bear full responsibility before the 
Center for Mental Health and Drug Dependence and the law. 
 
 
 
Date: ……../……../…….. 
 
Patient’s family representative or witness Patient 
(Signature or thumb-print, and full name) (Signature or thumb-
print, and full name) 
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APPENDIX  2: QUESTIONNAIRE 
 
RESEARCH QUESTIONNAIRE 
 
 
                                                       (Date of Registration):        ……     …….     ………. 
 (Case Number)                                                                                          DD       MM       YYY 
    
(Name) (Gender) (Age) 
 
 
 
 
 
(Male) 
 
(Female) 
 
0 
 
1 
 
 
 (Age): .....................(in Year) 
Marital Status Nationality Ethnicity  
(Single) 
(Married) 
(Divorced) 
(Widowed) 
(Separated ) 
(Co-habiting) 
0 
1 
2 
3 
4 
5 
(Cambodian) 
(Vietnamese) 
(Others) 
Q6-  (Specify): 
...............................
............ 
0 
1 
2 
 
 
(Khmer) 
(Vietnamese) 
(Chinese) 
(Cham) 
(Others) 
Q8- (Specify): 
.............................................. 
0 
1 
2 
3 
4 
 (Current address & Tel No.)  (Permanent address – if different) 
(#) ..........................   (St.) ................. 
(Village/Group):...................................... 
(Commune):............................................ 
(District):................................................. 
(Province/City):...................................... 
(Tel.):............................................... 
(#) ..........................   (St.)................................ 
(Village/Group):Q14.................................................. 
(Commune):............................................................... 
(District):.................................................................... 
(Province/City):................................................... 
(Tel.):................................................................... 
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Social Information 
 
(Current living arrangements) 
(Homeless) 
(Living with partner) 
(Living with parents) 
(Living in an NGO facility) 
0 
1 
2 
3 
 
 
 (Sharing house with friends or others who are drug 
users) 
(Sharing house with friends or others who are not 
drug users) 
(Others)   
(Specify): 
...................................................................................... 
4 
5 
6 
 
Referred by: 
(NGO) (0: No, 1: Yes) (Specify NGO) :  ................................................... 
(Family) (0: No, 1: Yes) 
(Police/Authority)  (0: No, 1: Yes); (Specify Police/Authority):..................... 
(Self-referred) (0: No, 1: Yes) 
(Others)  (0: No, 1: Yes); 
(Specify Other):................................................. 
 (Name and contact information of NGO worker/Police/Authority/support person)  
......................................................................................................................................................... 
(Education)  
(No education) 
 
(Primary School)  
 
(Junior High School) 
 
(Senior High School)  
 
(University) 
 
(Post University)  
0 
 
1 
 
2 
 
3 
 
4 
 
5 
  
(Date of Termination) 
 
............ / ............ / ............ 
DD        MM         YYYY 
 (Length in treatment – in days) 
............................... (No of days) 
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(Is partner a drug user)?  
(Partner is a drug user) 1 (Partner does not use drug) 0 
(Children)  
 
(No of children)  
  
 
 
(Work)   
(Currently not working) 
(Currently self-employed) 
0 
1 
(Currently working full-time) 
(Currently working part-time/ casual work) 
2 
3 
 
Drug Use: History and Current Use   
 
  
(Age of first use) 
 
Current types of 
Drug Use 
(Main route of use 
for current types 
of drug use) 
 
(Injection)            0 
(Smoke)               1 
(Snort)                 2  
(Inhale)                3 
(Oral)                   4 
 
Opiates (Heroin, morphine, 
codeine, etc.)    
ATS (Amphetamine Type 
Stimulants)    
How often did you use Heroin per week? ………………………………………… 
 
Diagnostic formulation based on ICD-10 (International Classification of Diseases, 10th 
Edition (Heroin Dependence) .......................................................................(Text) 
 
Number of missed dose / month 
 
Month 
Maximum Dose 
in the month 
(in mg) 
Number of Missed 
Dose (in the month) 
 
Retention 
(Tick the row of the month when 
patient drop out) 
1    
2    
3    
4    
5    
6    
7    
8    
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9    
10    
11    
12    
13    
14    
15    
 
Do you satisfy with MMT Service? 
 
* Not at all   (1) 
* Somewhat  (2) 
* Satisfy   (3) 
* Very satisfy   (4) 
 
Explain the reason: Why did you miss methadone dose? 
 
*Illness                  (1) 
*Busy at work/home  (2) 
* No money for travel  (3) 
* Arrested by Police/authority (4) 
* Other Reason   (5) 
(Specify) 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………....……………………
……………………………………………………………………………………………………… 
Why do you drop the treatment?  i.e after missing dose for more than 5 days. 
(This question can be asked to NGO case managers or the patients if we can find him/her in 
community or s/he return for Methadone dose again) 
 
*Illness                 (1) 
*Busy at work/home  (2) 
* No money for travel  (3) 
* Arrested by Police/authority (4) 
* Other Reason   (5) 
(Specify) 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
94 
 
………………………………………………………………………………....……………………
……………………………………………………………………………………………………… 
 
 
How far do you need to travel to MMT clinic? ................... (In Km) 
 
How did you come to MMT Clinic at the beginning? 
 
 (1) NGO Transportation 
 (2) Own Transpiration 
 
 
 
 
=========== 
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APPENDIX  3: LIST OF MONTHLY-ENROLLED PATIENTS 
Month Number 
JUL 2010 22 
AUG 2010 27 
SEP 2010 12 
MAR 2011 14 
APR 2011 5 
MAY 2011 19 
JUN 2011 8 
Total 107 
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APPENDIX  4: RECORD LIST OF PATIENTS RETAINED IN MMT 
(The dead patients were removed from this list.) 
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